Monitor BP in Patients on Injectable CGRP Antagonists (Aimovig, Etc)

April 2021

You’ll hear concerns about using an injectable CGRP antagonist (Aimovig, etc) for migraine prophylaxis in patients with CV risks.

Most data suggest that CGRP antagonists have minimal CV impact. But it’s mostly short-term data in young patients without CV risks.

Now an FDA review suggests new-onset or worsening hypertension with Aimovig (erenumab)...prompting labeling updates.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote